vs
Doximity, Inc.（DOCS）与自然阳光（NATR）财务数据对比。点击上方公司名可切换其他公司
Doximity, Inc.的季度营收约是自然阳光的1.5倍（$185.1M vs $123.8M），Doximity, Inc.净利率更高（33.3% vs 3.3%，领先29.9%），Doximity, Inc.同比增速更快（9.8% vs 4.7%），过去两年Doximity, Inc.的营收复合增速更高（25.2% vs 5.6%）
Doximity Inc成立于2010年，是面向医疗专业人士的线上社交服务平台，为平台会员提供精选医疗资讯、远程医疗工具，以及病例协作相关功能，助力医疗从业者高效交流信息、开展诊疗相关工作。
自然阳光产品公司（简称NSP）主营膳食补充剂与个人护理产品的生产制造，产品涵盖草本补充剂、维生素、矿物质制剂等品类。公司总部设于犹他州利希，生产工厂位于犹他州西班牙福克，是该领域知名的健康产品生产商。
DOCS vs NATR — 直观对比
营收规模更大
DOCS
是对方的1.5倍
$123.8M
营收增速更快
DOCS
高出5.0%
4.7%
净利率更高
DOCS
高出29.9%
3.3%
两年增速更快
DOCS
近两年复合增速
5.6%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $185.1M | $123.8M |
| 净利润 | $61.6M | $4.1M |
| 毛利率 | 89.9% | 72.5% |
| 营业利润率 | 38.9% | 4.3% |
| 净利率 | 33.3% | 3.3% |
| 营收同比 | 9.8% | 4.7% |
| 净利润同比 | -18.1% | 1379.4% |
| 每股收益（稀释后） | $0.31 | $0.23 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DOCSNATR
| Q4 25 | $185.1M | $123.8M | ||
| Q3 25 | $168.5M | $128.3M | ||
| Q2 25 | $145.9M | $114.8M | ||
| Q1 25 | $138.3M | $113.2M | ||
| Q4 24 | $168.6M | $118.2M | ||
| Q3 24 | $136.8M | $114.6M | ||
| Q2 24 | $126.7M | $110.6M | ||
| Q1 24 | $118.1M | $111.0M |
净利润DOCSNATR
| Q4 25 | $61.6M | $4.1M | ||
| Q3 25 | $62.1M | $5.3M | ||
| Q2 25 | $53.3M | $5.3M | ||
| Q1 25 | $62.5M | $4.7M | ||
| Q4 24 | $75.2M | $-321.0K | ||
| Q3 24 | $44.2M | $4.3M | ||
| Q2 24 | $41.4M | $1.3M | ||
| Q1 24 | $40.6M | $2.3M |
毛利率DOCSNATR
| Q4 25 | 89.9% | 72.5% | ||
| Q3 25 | 90.3% | 73.3% | ||
| Q2 25 | 89.2% | 71.7% | ||
| Q1 25 | 89.5% | 72.1% | ||
| Q4 24 | 91.6% | 72.0% | ||
| Q3 24 | 90.0% | 71.3% | ||
| Q2 24 | 89.3% | 71.4% | ||
| Q1 24 | 89.4% | 71.2% |
营业利润率DOCSNATR
| Q4 25 | 38.9% | 4.3% | ||
| Q3 25 | 37.8% | 7.0% | ||
| Q2 25 | 37.4% | 3.7% | ||
| Q1 25 | 35.2% | 5.4% | ||
| Q4 24 | 47.4% | 3.8% | ||
| Q3 24 | 38.8% | 4.6% | ||
| Q2 24 | 36.4% | 5.1% | ||
| Q1 24 | 35.5% | 4.2% |
净利率DOCSNATR
| Q4 25 | 33.3% | 3.3% | ||
| Q3 25 | 36.8% | 4.2% | ||
| Q2 25 | 36.5% | 4.6% | ||
| Q1 25 | 45.2% | 4.2% | ||
| Q4 24 | 44.6% | -0.3% | ||
| Q3 24 | 32.3% | 3.8% | ||
| Q2 24 | 32.7% | 1.2% | ||
| Q1 24 | 34.4% | 2.1% |
每股收益（稀释后）DOCSNATR
| Q4 25 | $0.31 | $0.23 | ||
| Q3 25 | $0.31 | $0.30 | ||
| Q2 25 | $0.27 | $0.28 | ||
| Q1 25 | $0.31 | $0.25 | ||
| Q4 24 | $0.37 | $-0.02 | ||
| Q3 24 | $0.22 | $0.23 | ||
| Q2 24 | $0.21 | $0.07 | ||
| Q1 24 | $0.20 | $0.12 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $64.8M | $93.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $979.3M | $161.6M |
| 总资产 | $1.2B | $261.1M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DOCSNATR
| Q4 25 | $64.8M | $93.9M | ||
| Q3 25 | $169.2M | $95.6M | ||
| Q2 25 | $137.3M | $81.3M | ||
| Q1 25 | $209.6M | $86.5M | ||
| Q4 24 | $165.3M | $84.7M | ||
| Q3 24 | $184.2M | $78.7M | ||
| Q2 24 | $111.4M | $68.7M | ||
| Q1 24 | $96.8M | $77.8M |
总债务DOCSNATR
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $2.1M |
股东权益DOCSNATR
| Q4 25 | $979.3M | $161.6M | ||
| Q3 25 | $1.1B | $166.7M | ||
| Q2 25 | $1.0B | $163.7M | ||
| Q1 25 | $1.1B | $167.1M | ||
| Q4 24 | $1.0B | $161.0M | ||
| Q3 24 | $961.2M | $162.6M | ||
| Q2 24 | $913.6M | $156.4M | ||
| Q1 24 | $901.4M | $159.7M |
总资产DOCSNATR
| Q4 25 | $1.2B | $261.1M | ||
| Q3 25 | $1.3B | $264.8M | ||
| Q2 25 | $1.2B | $254.9M | ||
| Q1 25 | $1.3B | $252.7M | ||
| Q4 24 | $1.2B | $240.9M | ||
| Q3 24 | $1.1B | $245.3M | ||
| Q2 24 | $1.1B | $235.8M | ||
| Q1 24 | $1.1B | $247.3M |
负债/权益比DOCSNATR
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.01× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $60.9M | $9.9M |
| 自由现金流经营现金流 - 资本支出 | — | $7.6M |
| 自由现金流率自由现金流/营收 | — | 6.1% |
| 资本支出强度资本支出/营收 | — | 1.9% |
| 现金转化率经营现金流/净利润 | 0.99× | 2.41× |
| 过去12个月自由现金流最近4个季度 | — | $28.8M |
8季度趋势，按日历期对齐
经营现金流DOCSNATR
| Q4 25 | $60.9M | $9.9M | ||
| Q3 25 | $93.9M | $18.5M | ||
| Q2 25 | $62.1M | $4.3M | ||
| Q1 25 | $98.5M | $2.6M | ||
| Q4 24 | $65.2M | $12.2M | ||
| Q3 24 | $68.3M | $9.6M | ||
| Q2 24 | $41.2M | $1.3M | ||
| Q1 24 | $63.9M | $2.2M |
自由现金流DOCSNATR
| Q4 25 | — | $7.6M | ||
| Q3 25 | — | $16.8M | ||
| Q2 25 | — | $3.0M | ||
| Q1 25 | — | $1.5M | ||
| Q4 24 | — | $10.0M | ||
| Q3 24 | — | $7.9M | ||
| Q2 24 | — | $-2.0M | ||
| Q1 24 | — | $-1.5M |
自由现金流率DOCSNATR
| Q4 25 | — | 6.1% | ||
| Q3 25 | — | 13.1% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 1.3% | ||
| Q4 24 | — | 8.5% | ||
| Q3 24 | — | 6.9% | ||
| Q2 24 | — | -1.9% | ||
| Q1 24 | — | -1.4% |
资本支出强度DOCSNATR
| Q4 25 | — | 1.9% | ||
| Q3 25 | — | 1.3% | ||
| Q2 25 | — | 1.2% | ||
| Q1 25 | 0.0% | 1.0% | ||
| Q4 24 | 0.0% | 1.9% | ||
| Q3 24 | 0.0% | 1.5% | ||
| Q2 24 | 0.0% | 3.0% | ||
| Q1 24 | 0.0% | 3.3% |
现金转化率DOCSNATR
| Q4 25 | 0.99× | 2.41× | ||
| Q3 25 | 1.51× | 3.46× | ||
| Q2 25 | 1.16× | 0.81× | ||
| Q1 25 | 1.58× | 0.55× | ||
| Q4 24 | 0.87× | — | ||
| Q3 24 | 1.55× | 2.21× | ||
| Q2 24 | 1.00× | 0.97× | ||
| Q1 24 | 1.57× | 0.94× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DOCS
| Subscription | $175.4M | 95% |
| Service Other | $9.7M | 5% |
NATR
| Other | $68.1M | 55% |
| General Health Products | $20.2M | 16% |
| Digestive Products | $13.8M | 11% |
| Cardiovascular Products | $12.1M | 10% |
| Personal Care Products | $4.4M | 4% |
| Immunity Products | $3.1M | 3% |
| Weight Management Products | $2.1M | 2% |
